Cumberland Partners Ltd Makes New $2.19 Million Investment in Chemed Corporation $CHE

Cumberland Partners Ltd bought a new stake in Chemed Corporation (NYSE:CHE) during the second quarter, Holdings Channel.com reports. The fund bought 4,500 shares of the company’s stock, valued at approximately $2,191,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Creekmur Asset Management LLC bought a new stake in Chemed in the 2nd quarter worth approximately $28,000. SVB Wealth LLC purchased a new stake in shares of Chemed in the 1st quarter valued at $30,000. WPG Advisers LLC bought a new position in shares of Chemed during the 1st quarter valued at $32,000. Parkside Financial Bank & Trust grew its holdings in shares of Chemed by 86.3% during the 2nd quarter. Parkside Financial Bank & Trust now owns 95 shares of the company’s stock valued at $46,000 after purchasing an additional 44 shares during the last quarter. Finally, Geneos Wealth Management Inc. raised its position in Chemed by 330.4% in the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock worth $61,000 after purchasing an additional 76 shares during the period. Institutional investors own 95.85% of the company’s stock.

Chemed Stock Performance

NYSE:CHE opened at $429.70 on Thursday. The firm has a market cap of $6.09 billion, a P/E ratio of 22.72, a P/E/G ratio of 2.69 and a beta of 0.43. Chemed Corporation has a fifty-two week low of $408.42 and a fifty-two week high of $623.60. The firm has a 50-day simple moving average of $442.35 and a two-hundred day simple moving average of $480.51.

Chemed (NYSE:CHE) last released its quarterly earnings data on Tuesday, October 28th. The company reported $5.27 EPS for the quarter, missing the consensus estimate of $5.39 by ($0.12). Chemed had a net margin of 11.02% and a return on equity of 25.89%. The business had revenue of $624.90 million for the quarter, compared to analysts’ expectations of $626.04 million. During the same period last year, the business earned $5.64 earnings per share. The company’s quarterly revenue was up 3.1% on a year-over-year basis. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. On average, equities research analysts predict that Chemed Corporation will post 21.43 EPS for the current year.

Chemed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Monday, November 17th will be issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, November 17th. Chemed’s dividend payout ratio is presently 12.69%.

Wall Street Analyst Weigh In

A number of brokerages have commented on CHE. Bank of America decreased their price target on Chemed from $610.00 to $595.00 and set a “buy” rating on the stock in a research note on Wednesday, September 10th. Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 30th. Jefferies Financial Group raised shares of Chemed from a “hold” rating to a “buy” rating and increased their price target for the company from $490.00 to $550.00 in a research report on Tuesday, September 2nd. Oppenheimer lowered their price objective on shares of Chemed from $650.00 to $580.00 and set an “outperform” rating for the company in a research note on Thursday, July 31st. Finally, Royal Bank Of Canada reduced their price target on Chemed from $589.00 to $572.00 and set an “outperform” rating on the stock in a report on Monday, November 10th. Four investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $574.25.

Insiders Place Their Bets

In other news, CEO Kevin J. Mcnamara sold 3,000 shares of the company’s stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $461.28, for a total transaction of $1,383,840.00. Following the completion of the sale, the chief executive officer owned 96,197 shares of the company’s stock, valued at $44,373,752.16. This represents a 3.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Patrick P. Grace sold 150 shares of the company’s stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $463.39, for a total transaction of $69,508.50. Following the sale, the director directly owned 3,397 shares of the company’s stock, valued at approximately $1,574,135.83. This represents a 4.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 3.29% of the company’s stock.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.